Regencell Bioscience Holdings Limited (RGC)
NASDAQ: RGC · Real-Time Price · USD
22.99
+12.63 (121.91%)
At close: Jul 3, 2025, 1:00 PM
19.90
-3.09 (-13.44%)
After-hours: Jul 3, 2025, 4:59 PM EDT
Company Description
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong.
The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder.
Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Regencell Bioscience Holdings Limited
| Country | Hong Kong |
| Founded | 2014 |
| IPO Date | Jul 16, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Yat-Gai Au |
Contact Details
Address: Chinachem Leighton Plaza, 9th Floor Causeway Bay Hong Kong | |
| Phone | 852 2155 0823 |
| Website | regencellbioscience.com |
Stock Details
| Ticker Symbol | RGC |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| IPO Price | $9.50 |
| CIK Code | 0001829667 |
| CUSIP Number | G7487R100 |
| ISIN Number | KYG7487R1002 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Yat-Gai Au | Founder, Chairman and Chief Executive Officer |
| Michelle Chan | Financial Controller and Principal Financial Officer |
| Wai Hong Chung | Chief Operating Officer, Chief Strategy Officer and Director |
| Antonia Assang | Senior Vice President of Project Management |
| Yat-Pui Au | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 30, 2025 | 6-K | Report of foreign issuer |
| Jun 30, 2025 | 6-K | Report of foreign issuer |
| Jun 17, 2025 | 6-K | Report of foreign issuer |
| Jun 2, 2025 | 6-K | Report of foreign issuer |
| Mar 13, 2025 | SCHEDULE 13D/A | Filing |
| Jan 15, 2025 | 6-K | Report of foreign issuer |
| Oct 25, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Jun 20, 2024 | 6-K | Report of foreign issuer |
| Jan 2, 2024 | 6-K | Report of foreign issuer |
| Dec 15, 2023 | 6-K | Report of foreign issuer |